TIL Therapy's Next Chapter: How Do We Capitalize on Its Potential?

Wed, Mar 17 | 04:45 PM - 05:25 PM
Track 2

Session details:

The challenge now with TIL therapies is moving from clinical validation to broad clinical adoption. Despite demonstrated activity in solid tumors, manufacturing complexity, logistical demands, scalability, and consistency remain barriers to making TIL therapy a practical option for more patients. As next-generation approaches emerge, what will it take to capitalize on the full potential of TIL-based treatments? 

Discussion Points 

  • What are the biggest barriers preventing broader adoption of TIL therapy? 
  • How can manufacturing, logistics, and scalability be improved without compromising efficacy? 
  • Can engineered or next-generation TIL platforms overcome today's operational limitations? 
  • What lessons from TIL development can be applied across the broader cell therapy field? 
  • What will it take for TIL therapy to become a commercially viable, mainstream treatment? 

Moderator:

Stephanie Goff, MD, FACS, FSSO
Stephanie Goff, MD, FACS, FSSO Director, CCR Surgical Oncology Services; Senior Research Physician National Cancer Institute, NIH

Speakers:

Chantal Bernatchez, PhD
Chantal Bernatchez, PhD Sr Director, CTMC; Associate Director, Cell Therapy Process Development MD Anderson Cancer Center
Parameswaran Hari, MD
Parameswaran Hari, MD CMO Obsidian Therapeutics
Pamela Ohashi, PhD, FRSC
Pamela Ohashi, PhD, FRSC Senior Scientist & Director, Tumor Immunotherapy Program Princess Margaret Cancer Center / University of Toronto
Industry Specific Content:
Cell Therapy
Track:
Track 2: Cell Therapy